Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 December 2018 | Story Leonie Bolleurs | Photo Anja Aucamp
Research possibilities of zebrafish exposed
Leading global genetics laboratories are replacing research on human and animal populations with zebrafish, says Prof Paul Grobler, Head of the UFS Department of Genetics.

The UFS Department of Genetics is on par with current research trends in terms of their zebrafish project. About a year has passed since they seriously started focusing on the potential of this tiny four-centimetre-long fish, and the possibilities are hugely exciting.

Looks are deceiving

Leading global genetics laboratories are replacing research on human and animal populations with zebrafish due to several fascinating reasons, of which the most profound is probably that the zebrafish share large portions of its genome with mammals. For genetics researchers this may make a lot of sense, but most people battle to see any resemblance between a six-foot-tall rugby player or 600 kg buffalo and a small, nearly transparent fish. It is in the detail, the researchers say.

Fast, effective, and visible

“The complete genome sequence of the zebrafish is known, and as much as 84% of genes known to be associated with human disease have zebrafish counterparts,” explains Head of Department, Prof Paul Grobler. Another advantage is the fast breeding rate and short generation time, and the fact that some research is ethically more justifiable when done on fish larvae rather than on adult mammals. The fact that zebrafish embryos are virtually transparent, also allow researchers to examine the development of internal structures without effort. Every blood vessel in a living zebrafish embryo is visible under a low-power microscope.

Multidisciplinary

Zebrafish provide research potential for many different study fields besides that of Prof Grobler and his team, Sue Rica Schneider and Dr Willem Coetzer. In the near future, they aim to have undergraduate students use zebrafish as a research model to develop a real sense of research and laboratory work. The Department of Chemistry are also initiating research on zebrafish housed in the Department of Genetics.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept